Market News
Stay updated with the latest market trends, earnings, and economic indicators.
RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September
RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.
RPG Life Sciences Q4 Results: Operating performance strong, base quarter one-off impacts profit
Shares of RPG Life Sciences Ltd ended at ₹2,024.05, down by ₹34.70, or 1.69%, on the BSE.
Siemens Healthineers eyes collaboration with Karnataka on life sciences, healthtech centres of excellence: Priyank Kharge
Siemens Healthineers is exploring a collaboration with the Karnataka government to bolster upcoming centers of excellence in life sciences, healthtech, and medical products. Discussions focused on skilling, joint incubation, and partnerships to align with the state's deeptech initiatives, further strengthening the company's presence in Bengaluru.
H.C. Wainwright reiterates Buy on Achieve Life Sciences stock By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy on Achieve Life Sciences stock By Investing.comInvesting.com India
Stock to buy: Jefferies lists 10 reasons to buy its top CRDMO pick Sai Life Sciences
Jefferies has initiated coverage on Sai Life Sciences with a 'Buy' rating and a Rs 1,300 target price, citing its integrated 'follow-the-molecule' model and strong growth outlook. The brokerage highlighted the company's healthy pipeline, global presence, and clean balance sheet as key investment drivers, projecting significant upside potential.
CCL Products, Sai Life Sciences on Mayuresh Joshi’s watchlist for earnings strength
Mayuresh Joshi, Director of Research at Marketsmith India, is watching earnings-resilient sectors such as consumer discretionary, banking, and pharmaceuticals as market remains volatile. Along with CCL Products and Sai Life Sciences, Strides Pharma Science and ICICI Bank are on his watchlist, while Vishal Mega Mart remains a domestic consumption play worth tracking.
Sai Life hits record high in weak market; rebounds 5% from day's low
Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.
Novo Holdings scales up India bets with bigger cheques, focus on mature healthcare assets
The life sciences investor is increasing ticket sizes and doubling down on speciality care and healthcare services as India emerges as a key deployment market in Asia.
Indian drugmaker Sai Life Sciences to boost headcount by about 20% amid global demand upswing
Sai Life Sciences will boost its workforce by over 700 employees next financial year. This expansion supports growing global demand for its services. The company is increasing capacity to meet this demand. New hires will focus on scientific, technical, and management roles. This move reflects a broader trend of global pharma companies expanding in India.
Telangana aims to make Hyderabad leading life sciences hub amid Centre’s Biopharma SHAKTI boost
Telangana is set to emerge as a major beneficiary of the Biopharma SHAKTI scheme, led by its well-established industry clusters, robust research ecosystem, and strong manufacturing capabilities. It already houses leading global pharmaceutical companies, such as Amgen, Zoetis, Evernorth, HCA Healthcare, Eli Lilly and Sanofi.
Momentum Stocks: TRF, Pace Digitek, Om Infra gain up to 10% on sheer momentum
Notable names hitting new one-year highs included Kirloskar Oil Engines, Syrma SGS Technology, Sai Life Sciences, Schneider Electric Infrastructure, AIA Engineering, Laurus Labs, Emcure Pharmaceuticals, GE Vernova T&D India, Apar Industries.
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
India’s listing and IPO norms are structurally incompatible with biotechnology innovation, where companies often spend a decade or more in research and clinical trials before earning their first rupee of revenue, the Biocon chairperson has said